Status:
COMPLETED
Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine
Lead Sponsor:
Psych Atlanta
Conditions:
Treatment Resistant Depression
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to assess the efficacy and safety of intranasal esketamine as maintenance antidepressant therapy in patients who have demonstrated clinical improvement with off-label intravenous racem...
Detailed Description
This is a retrospective case series of ten consecutive outpatients with treatment-resistant depression who all had a clinically meaningful response when treated with intravenous racemic ketamine and w...
Eligibility Criteria
Inclusion
- Diagnosis of major depression, recurrent, severe without psychotic symptoms according to criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V). Must be diagnosed with Treatment resistant depression.
- 18 years old and up Patients had a clinically meaningful response to a course of IV racemic ketamine
Exclusion
- Active substance abuse, psychosis, significant medical comorbidities, or axis II diagnosis that would interfere with the reliability of outcome measures or response to pharmacotherapy.
Key Trial Info
Start Date :
September 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2021
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04856124
Start Date
September 1 2018
End Date
March 1 2021
Last Update
April 23 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PsychAtlanta
Marietta, Georgia, United States, 30060